Antibodies that selectively bind and destroy cancer cells represent some of the most promising cancer therapy approaches being developed today. Several of these antibodies have reached the market, including cetuximab (Erbitux®, ImClone Systems), which targets the epidermal growth factor receptor (EGFR) protein. However, a study conducted at the Dana-Farber Cancer Institute and the Ludwig Center at Dana-Farber/Harvard Medical School now suggests that antibodies binding a particular protein conformation, caused by hyperactivation, might have distinct therapeutic advantages over antibodies, like cetuximab, that bind to wild-type (normal) target proteins.
The study, led by Dana-Farber Cancer Institute's Dr. Kwok-Kin Wong, and published today in the Journal of Clinical Investigation, is part of a multi-center, international effort to assess the clinical potential of the 806 antibody. The 806 antibody was discovered by scientists at the Ludwig Institute for Cancer Research. The antibody targets EGFR only when the receptor has been activated by mutations, by the protein's over-expression or by amplification of the EGFR gene. In the present study, Dr. Wong compared the action of cetuximab and 806 in a mouse model of non-small cell lung cancer (NSCLC) caused by different activating mutations in EGFR.. The 806 antibody caused a dramatic tumor regression in the mice, while cetuximab did not.
"Cetuximab only works on a subset of patients with lung cancers," says Wong. "We think the 806 antibody might benefit those patients who respond to cetuximab but, more importantly, might also be effective for those patients who don't." According to Dr. Wong, approximately 10-30 percent of patients with NSCLC and 5 percent of patients with squamous cell lung cancers have EGFR activating mutations. Some brain tumors also have EGFR activating mutations that are – in animal studies – responsive to the 806 antibody. A phase I clinical trial of the 806 antibody has been completed in Melbourne, Australia by the Ludwig Institute for Cancer Research co-authors. The antibody was shown to target a variety of cancers, including squamous cell lung cancer, with no targeting of normal tissues and no toxicity.
Sarah L. White | EurekAlert!
Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP
New weapon against Diabetes
09.12.2016 | Eidgenössische Technische Hochschule Zürich (ETH Zürich)
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy